AR105606A1 - Compuesto de fenilamina substituida, composición farmacéutica y combinación que lo comprenden y su uso para fabricar un medicamento - Google Patents
Compuesto de fenilamina substituida, composición farmacéutica y combinación que lo comprenden y su uso para fabricar un medicamentoInfo
- Publication number
- AR105606A1 AR105606A1 ARP160102392A ARP160102392A AR105606A1 AR 105606 A1 AR105606 A1 AR 105606A1 AR P160102392 A ARP160102392 A AR P160102392A AR P160102392 A ARP160102392 A AR P160102392A AR 105606 A1 AR105606 A1 AR 105606A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- heterocycloalkyl
- cycloalkyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Un compuesto de fenilamina substituida caracterizado porque es de fórmula (1), o una de sus sales, en donde, A¹ es CH; A² se selecciona de CR¹³ y N; R¹ se selecciona de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo C₄₋₇, fenilo, heteroarilo C₅₋₆, alcoxi C₁₋₆, -O-(cicloalquilo C₃₋₇) y NR¹⁰ᵃR¹⁰ᵇ; en donde el cicloalquilo C₃₋₇, heterocicloalquilo C₄₋₇, fenilo, heteroarilo C₅₋₆ y -O-(cicloalquilo C₃₋₇) están opcionalmente sustituidos con 1 a 3 grupos independientemente seleccionados de hidroxi, metoxi, alquilo C₁₋₃ y halógeno; L¹ es un grupo conector seleccionado de -C(O)- y -S(O)ₙ-, en donde n representa de 1 a 2; R³ se selecciona de hidrógeno, halógeno, metilo, metoxi y ciano; R⁴ se selecciona de hidrógeno, halógeno, metilo, metoxi y ciano; R² se selecciona de hidrógeno, halógeno, Ar, Cy, X, NR⁵ᵃR⁵ᵇ y -C(O)-R¹⁵; Ar se selecciona de fenilo y heteroarilo C₅₋₆, cada uno de los cuales está opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de halógeno y -L²-R⁷; L² es un grupo conector seleccionado de un enlace, -(CH₂)ₘ-, -O(CH₂)ₘ-, -alquenilo C₂₋₄-, -O-(alquinilo C₂₋₄)-, -(CH₂)ₚ-NH-(CH₂)q-, y -(CH₂)ₚC(O)-(CH₂)q-; en donde m representa de 1 a 4 y p y q representan independientemente de 0 a 4; R⁷ se selecciona de hidrógeno; hidroxi; NR⁸ᵃR⁸ᵇ; heterocicloalquilo C₄₋₇ opcionalmente sustituido con uno o dos grupos alquilo C₁₋₃; cicloalquilo C₃₋₇; alcoxi C₁₋₆ opcionalmente sustituido con un grupo NR¹⁴ᵃR¹⁴ᵇ; y fenilo opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de halógeno, metoxi y metilo; Cy se selecciona de cicloalquilo C₃₋₇, heterocicloalquilo C₄₋₇, cicloalquenilo C₅₋₇ y heterocicloalquenilo C₅₋₇, cada uno de los cuales está opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de alquilo C₁₋₃, alcoxi C₁₋₃, heterocicloalquilo C₄₋₇, NR¹¹ᵃR¹¹ᵇ, =O, -C(O)-R¹⁵ y -C(O)O-R¹⁵; X se selecciona de alquilo C₁₋₆, alquenilo C₂₋₆ y alcoxi C₁₋₆, cada uno de los cuales está opcionalmente sustituido con 1 a 3 grupos independientemente seleccionados de hidroxi, metoxi, halógeno, NR¹³ᵃR¹³ᵇ y heterocicloalquilo C₄₋₇, en donde el heterocicloalquilo C₄₋₇ está opcionalmente sustituido con 1 a 3 grupos alquilo C₁₋₃; R⁵ᵃ se selecciona de hidrógeno; alquilo C₁₋₆ opcionalmente sustituido con un grupo seleccionado de Ar y Cy; -C(O)-R⁹; -C(O)-OR⁹; y -SO₂-R⁹; R⁵ᵇ se selecciona de hidrógeno y alquilo C₁₋₃; R⁸ᵃ y R⁸ᵇ se seleccionan independientemente de hidrógeno y alquilo C₁₋₃; R⁹ se selecciona de alquilo C₁₋₆, cicloalquilo C₃₋₇, heterocicloalquilo C₄₋₇, fenilo y heteroarilo C₅₋₆; R¹⁰ᵃ y R¹⁰ᵇ se seleccionan independientemente de hidrógeno y alquilo C₁₋₃; R¹¹ᵃ y R¹¹ᵇ se seleccionan independientemente de hidrógeno y alquilo C₁₋₃; R¹² se selecciona de hidrógeno, halógeno y metilo; R¹³ se selecciona de hidrógeno, alquilo C₁₋₃, -C(O)-(heterocicloalquilo C₄₋₇), -C(O)-(alquilo C₁₋₃) y -C(O)-(cicloalquilo C₃₋₇); R¹³ᵃ y R¹³ᵇ se seleccionan independientemente de hidrógeno y alquilo C₁₋₃; R¹⁴ᵃ y R¹⁴ᵇ se seleccionan independientemente de hidrógeno y alquilo C₁₋₃; y R¹⁵ se selecciona de alquilo C₁₋₆, Ar, cicloalquilo C₃₋₇ y heterocicloalquilo C₄₋₇.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382418 | 2015-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105606A1 true AR105606A1 (es) | 2017-10-18 |
Family
ID=53887051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102392A AR105606A1 (es) | 2015-08-07 | 2016-08-04 | Compuesto de fenilamina substituida, composición farmacéutica y combinación que lo comprenden y su uso para fabricar un medicamento |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10479792B2 (es) |
| EP (1) | EP3331885B1 (es) |
| JP (1) | JP6838045B2 (es) |
| KR (1) | KR102652898B1 (es) |
| CN (1) | CN108137599B (es) |
| AR (1) | AR105606A1 (es) |
| AU (1) | AU2016307230B2 (es) |
| BR (1) | BR112018002597B1 (es) |
| CA (1) | CA2994997C (es) |
| CY (1) | CY1124151T1 (es) |
| DK (1) | DK3331885T3 (es) |
| ES (1) | ES2856899T3 (es) |
| HR (1) | HRP20210402T1 (es) |
| HU (1) | HUE052932T2 (es) |
| IL (1) | IL257336B (es) |
| LT (1) | LT3331885T (es) |
| MY (1) | MY197042A (es) |
| PL (1) | PL3331885T3 (es) |
| PT (1) | PT3331885T (es) |
| RS (1) | RS61434B1 (es) |
| RU (1) | RU2734877C2 (es) |
| SI (1) | SI3331885T1 (es) |
| TW (1) | TWI746454B (es) |
| WO (1) | WO2017025416A1 (es) |
| ZA (1) | ZA201800733B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190278A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
| EA039324B1 (ru) * | 2017-11-06 | 2022-01-13 | Новартис Аг | 5,6–конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний |
| RU2717960C1 (ru) * | 2019-08-05 | 2020-03-27 | Федеральное Государственное бюджетное учреждение "27 Научный центр" Министерства обороны Российской Федерации | СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ α-БРОМАРИЛАЦЕТАЛЬДЕГИДОВ С ИСПОЛЬЗОВАНИЕМ БРОМИДА МЕДИ (II) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010059418A1 (en) * | 2008-11-19 | 2010-05-27 | The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services | Substituted triazine and purine compounds, methods of inhibiting cruzain and rhodesain and methods of treating chagas disease and african trypanosomiasis |
| SG10201403138WA (en) * | 2009-07-02 | 2014-08-28 | Sanofi Sa | Novel 2,3-dihydro-1h-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof and pharmaceutical use thereof |
| UY35400A (es) * | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| WO2014151630A2 (en) * | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| WO2014151729A1 (en) * | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| LT3083627T (lt) * | 2013-12-19 | 2018-12-27 | Novartis Ag | [1,2,4]triazolo[1,5-a]pirimidino dariniai kaip protozoano proteasomos inhibitoriai, skirti parazitinių ligų tokių kaip leišmaniozė, gydymui |
-
2016
- 2016-08-03 WO PCT/EP2016/068592 patent/WO2017025416A1/en active Application Filing
- 2016-08-03 CN CN201680057096.2A patent/CN108137599B/zh active Active
- 2016-08-03 CA CA2994997A patent/CA2994997C/en active Active
- 2016-08-03 HU HUE16747519A patent/HUE052932T2/hu unknown
- 2016-08-03 DK DK16747519.3T patent/DK3331885T3/da active
- 2016-08-03 AU AU2016307230A patent/AU2016307230B2/en active Active
- 2016-08-03 LT LTEP16747519.3T patent/LT3331885T/lt unknown
- 2016-08-03 SI SI201631098T patent/SI3331885T1/sl unknown
- 2016-08-03 JP JP2018506295A patent/JP6838045B2/ja active Active
- 2016-08-03 PT PT167475193T patent/PT3331885T/pt unknown
- 2016-08-03 BR BR112018002597-6A patent/BR112018002597B1/pt active IP Right Grant
- 2016-08-03 MY MYPI2018700471A patent/MY197042A/en unknown
- 2016-08-03 RU RU2018107657A patent/RU2734877C2/ru active
- 2016-08-03 ES ES16747519T patent/ES2856899T3/es active Active
- 2016-08-03 KR KR1020187005944A patent/KR102652898B1/ko active IP Right Grant
- 2016-08-03 US US15/750,896 patent/US10479792B2/en active Active
- 2016-08-03 EP EP16747519.3A patent/EP3331885B1/en active Active
- 2016-08-03 PL PL16747519T patent/PL3331885T3/pl unknown
- 2016-08-03 RS RS20210152A patent/RS61434B1/sr unknown
- 2016-08-04 TW TW105124717A patent/TWI746454B/zh active
- 2016-08-04 AR ARP160102392A patent/AR105606A1/es unknown
-
2018
- 2018-02-04 IL IL257336A patent/IL257336B/en active IP Right Grant
- 2018-02-05 ZA ZA2018/00733A patent/ZA201800733B/en unknown
-
2021
- 2021-03-09 HR HRP20210402TT patent/HRP20210402T1/hr unknown
- 2021-03-11 CY CY20211100209T patent/CY1124151T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR095885A1 (es) | Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2 | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| EA201790896A1 (ru) | Пролекарства фенольных агонистов trpv1 | |
| AR102972A1 (es) | Compuestos de dihidropirimidin-2-ona y su uso médico | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR097253A1 (es) | Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| CL2020002588A1 (es) | Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016) | |
| AR105606A1 (es) | Compuesto de fenilamina substituida, composición farmacéutica y combinación que lo comprenden y su uso para fabricar un medicamento | |
| AR100776A1 (es) | Compuestos herbicidas | |
| AR101222A1 (es) | Derivados de piridona | |
| AR100439A1 (es) | Derivados de carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |